Tango Therapeutics (TNGX)
(Delayed Data from NSDQ)
$7.76 USD
-0.01 (-0.13%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $7.76 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Tango Therapeutics, Inc. [TNGX]
Reports for Purchase
Showing records 1 - 20 ( 40 total )
Company: Tango Therapeutics, Inc.
Industry: Unclassified
We Eagerly Await Initial TNG908 Data; 4Q23 Financials; Adjusting PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Tango Therapeutics, Inc.
Industry: Unclassified
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Optimized Entry and Exit Levels for TNGX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
TNG908 Clinical Data Slated for 2024; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Preclinical Data For TNG348 Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
TNG908 Derisked by Competitor Data; Raising PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
This PRMT5i Data Deserves a PR; MRTX Data Validates TNG908, TNG462 Mechanism
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
USP1 in Focus; Remain Excited on Prospects for TNG348
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Q1 Financials; First TNG908 Clinical Data - All Signals in The Right Direction
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R